


Figure 1



00645071-082300

Figure 2



Figure 2A
Fragment #1
(NF-kB mimicry)

Figure 2B
Fragment #2
(2'-5'A Binding)




Figure 2C
Fragment #3
(Cdk6 chain A mimicry)

**Figures 2A to 2C. Three Dimensional Representations of Three
RNase L Fragments Involved in Anti-Apoptosis in PBMCs of CFS
Patients**

006280-T2054960

05645071-0810-200




Figure 3. Analysis of PBMC Extracts for RNase L Protein and Related 2'5'A Binding Fragments in Healthy Controls and CFS Patients Before and After Therapy with Mismatched dsRNA. Lane 1 – recombinant RNase L; Lanes 2, 3, 4, and 5 – Healthy controls; Lane 6 – Patient A before therapy; Lane 7 – Patient A after therapy; Lane 8 – Patient B before therapy; Lane 9 – Patient B after therapy; Lane 10 – Patient C before therapy; Lane 11 – Patient C after therapy; Lane 12 – Patient D before therapy; Lane 13 – Patient D after therapy; Lane 14 – Patient D after cessation of therapy for six months

Figure 4




Figure 4. Western Blot Analysis of PBMC Extracts for RNase L Protein and Related Fragments in Healthy Controls and CFS Patients Before and After Therapy with Mismatched dsRNA Lane 1 – recombinant RNase L; Lanes 2, 3, 4, and 5 – Healthy controls; Lane 6 – Patient A before therapy; Lane 7 – Patient A after therapy; Lane 8 – Patient B before therapy; Lane 9 – Patient B after therapy; Lane 10 – Patient C before therapy; Lane 11 – Patient C after therapy; Lane 12 – Patient D before therapy; Lane 13 – Patient D after therapy; Lane 14 – Patient D after cessation of therapy for six months. [Arrow to left indicates 80 kDa native RNase L. Arrows to right indicate RNase L-related fragments visible in Lanes 6, 8, 10, 11, 12, and 14. Approximate molecular weights (from top to bottom) are: 65 kDa, 55 kDa, 37 kDa, and 30 kDa]

006230"1"082300